Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Perceptive Instruments Earn Out Payment

13 Feb 2015 07:00

RNS Number : 8002E
Instem plc
13 February 2015
 



13 February 2015

Instem plc("Instem" or the "Company")

 

Perceptive Instruments Earn Out Payment

 

Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, announces that it has paid in full the performance based earn out of £300,000 in respect of the acquisition of Perceptive Instruments Limited ('Perceptive').

 

Earn Out Payment

As a result of Perceptive achieving all of the specified earn out targets for the period to 21 November 2014, the Vendors have been paid the maximum additional consideration of £300,000 in accordance with the Acquisition Agreement.

 

Background to the Acquisition

Instem acquired Perceptive in November 2013 for a maximum consideration of £1.3m, including the conditional earn out, marking the Company's entrance into the in vitro R&D marketplace.

 

Perceptive is located in Suffolk, UK, and develops, manufactures and supplies software and hardware products for in vitro study data collection and study management in the genetic toxicology, microbiology and immunology markets. Perceptive is the leading technology provider within its niche market and there are few competitors active in the space.

 

Phil Reason, CEO of Instem, said: "The acquisition of Perceptive has been a success, not only in terms of the financial contribution the acquisition has made to date, but also in terms of expanding the Company's offering into the in vitro data collection and study management in the genetic toxicology, microbiology and immunology markets We are looking forward to another strong contribution from this area in 2015 and beyond."

 

For further information, please contact:

Instem plc

Tel: +44 (0) 1785 825 600

Phil Reason, CEO

www.instem.com

Nigel Goldsmith, CFO

 

 

 

N+1 Singer (Nominated Adviser & Broker)

Tel: +44 (0) 20 7496 3000

Richard Lindley

 

Nick Owen

 

 

 

Walbrook PR Ltd

Tel: +44 (0) 20 7933 8780 or

Paul Cornelius

instem@walbrookpr.com

Sam Allen

 

Nick Rome

 

 

 

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market, delivering compelling solutionsfor data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.

 

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

 

Instem supports over 400 clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.

 

To learn more about Instem solutions and its mission, please visit www.instem.com

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAKAAFSDSEFF
Date   Source Headline
15th Feb 201811:05 amRNSSecond Price Monitoring Extn
15th Feb 201811:00 amRNSPrice Monitoring Extension
29th Jan 20187:00 amRNSDirector/PDMR Shareholding
23rd Jan 20185:27 pmRNSHolding(s) in Company
16th Jan 20187:01 amRNSContract Win
16th Jan 20187:00 amRNSTrading Statement
5th Oct 201711:30 amRNSHolding(s) in Company
29th Sep 201712:17 pmRNSIssue of Equity & Total Voting Rights
26th Sep 20177:00 amRNSHalf-year Report
21st Sep 20175:57 pmRNSHolding(s) in Company
4th Sep 20177:00 amRNSNotice of Results
31st May 20178:39 amRNSPayment of consideration and total voting rights
19th May 20175:00 pmRNSHolding(s) in Company
18th May 201710:24 amRNSResult of AGM
9th May 20172:25 pmRNSIssue of Equity and Total Voting Rights
28th Apr 20175:12 pmRNSHolding(s) in Company
26th Apr 20177:00 amRNSUS Government Contract
21st Apr 20177:00 amRNSPosting of Annual Report and Notice of AGM
4th Apr 201710:10 amRNSHolding(s) in Company
4th Apr 201710:10 amRNSHolding(s) in Company
29th Mar 20173:46 pmRNSHolding(s) in Company
28th Mar 20177:00 amRNSFinal Results
9th Mar 20177:00 amRNSInvestor Teach-in
7th Mar 20177:00 amRNSNotice of Results
16th Jan 20177:00 amRNSTrading Statement
9th Jan 20172:30 pmRNSAppointment of Chief Operating Officer
9th Jan 20177:00 amRNSGrowth & Innovation Forum
20th Dec 20165:23 pmRNSHolding(s) in Company
19th Dec 20164:58 pmRNSHolding(s) in Company
15th Dec 20167:00 amRNSRevised Earn Out Settlement
21st Nov 20167:00 amRNSTrading Statement
22nd Sep 20167:00 amRNSHolding(s) in Company
21st Sep 20168:08 amRNSIssue of Equity
19th Sep 20167:00 amRNSHalf-year Report
5th Sep 20163:40 pmRNSEarnings Enhancing Acquisition of Notocord®
24th Aug 20167:00 amRNSTrading Update and Notice of Half-Year Results
9th Jun 20165:32 pmRNSIssue of Equity
1st Jun 20161:55 pmRNSHolding(s) in Company
31st May 20167:00 amRNSAcquisition, Issue of Equity & Total Voting Rights
26th May 20165:42 pmRNSResult of AGM
19th May 20162:31 pmRNSHolding(s) in Company
16th May 20164:30 pmRNSIssue of Equity and Total Voting Rights
7th Apr 20169:42 amRNSHolding(s) in Company
5th Apr 20167:00 amRNSFinal Results
4th Apr 20167:00 amRNSFour SEND related contract wins
15th Mar 20167:00 amRNSTwo SEND Submit Contract Wins
14th Mar 20167:00 amRNSNotice of Results
3rd Mar 201610:56 amRNSHolding(s) in Company
29th Feb 20169:56 amRNSHolding(s) in Company (Correction)
26th Feb 20169:26 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.